Bradley A McGregor MDClinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA
Dr. Bradley A. McGregor is currently a Medical Oncologist specializing in genitourinary malignancies at the Dana-Farber Cancer Institute. Completing his undergraduate and medical school education at Tufts University; he then joined the United States Air Force at the San Antonio Uniformed Services Health Education Consortium. He served in Afghanistan as the Deputy Commander for the NATO led Medical Training Advisory Group where he mentored the Afghan physicians. Reaching the rank of Lieutenant Colonel and receiving the Meritorious Service medal, Dr McGregor left the Air Force in July of 2016 and came to Dana Farber. A senior physician, he has served as the Clinical Director of the Lank Center for Genitourinary Oncology at DFCI since 2016. He has served as principal investigator for several trials while leading IITs in treatment of rare genitourinary malignancies, non-clear cell renal cell carcinoma.
DisclosuresDr. McGregor reports the following disclosures:
BAM discloses payment for consulting with Bayer, Astellas, Astra Zeneca, Seattle Genetics, Exelixis, Nektar, Pfizer, Janssen, Genentech, Eisai , EMD Serono, BMS and Calithera. He received research support to Dana Farber Cancer Institute (DFCI) from Bristol Myers Squibb, Calithera, Exelixis, Seattle Genetics.
Recent Contributions to PracticeUpdate:
- Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPC
- Combination Immunotherapy for Advanced Bladder Cancer of Variant Histologies
- Immunotherapy for GU Malignancies in the Elderly
- Frontline RCC Treatment From ASCO GU 2019: Practice Implications
- Efficacy and Quality of Life Outcomes With Ribociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer
- ESMO 2018: Cabozantinib After Checkpoint Blockade for Advanced RCC
- Balixafortide Plus Eribulin for Metastatic Breast Cancer
- ESMO 2018: Overall Survival With Palbociclib Plus Fulvestrant
- ESMO 2018: Alpelisib Plus Fulvestrant for Hormone Receptor Positive Metastatic Breast Cancer
- TKI Monotherapy Still Has a Role in mRCC Front-Line Therapy